TOP STORIES
respiratory
Lung cancer

Lung Foundation welcomes new option for advanced lung cancer

Around 4,500 people living with advanced lung cancer are set to benefit from the new PBS listing of a checkpoint immunotherapy. Nivolumab (Opvido) has been listed on the PBS  for locally advanced or metastatic non-small cell lung cancer and advanced (stage IV) clear cell variant renal cell carcinoma. The move to reimburse the drug represents ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic